

ABSTRACT

Therapeutics of bone resorption-associated diseases,
which contain selective iNOS inhibitors as the active
ingredient, are useful as a therapeutic of osteoporosis, a
5 bone mass-maintenance drug, a bone resorption retardant, an
inhibitor of bone metastasis of cancer cells, a therapeutic
of nephritis, a progression retardant of chronic renal
failure, etc.